Northwest Biotherapeutics, a Biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency ( MHRA ) of a license for manufacture of GMP (clinical grade) Cell therapy products at its Sawston, UK facility.
The MHRA license approval enables the manufacturing of DCVax-L products to get under way at the Sawston facility in addition to continuing at the smaller GMP Facility in London. The license also permits the import and GMP manufacture of other Cell Therapy products under the UK
